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Perturbed action of signal transduction pathways, including the mitogen-activated protein (MAP) kinase pathways, is
one of the hallmarks of many cancers. While the implication of the typical MAP kinase pathways ERK1/2-MEK1/2,
p38MAPK and JNK is well established, recent findings illustrate that the atypical MAP kinase ERK3/4-MK5 may also be
involved in tumorigenic processes. Remarkably, the ERK3/4-MK5 pathway seems to possess anti-oncogenic as well
as pro-oncogenic properties in cell culture and aninal models. This review summarizes the mutations in the genes
encoding ERK3, ERK4 and MK5 that have been detected in different cancers, reports aberrant expression levels of
these proteins in human tumours, and discusses the mechanisms by which this pathway can induce senescence,
stimulate angiogenesis and invasiveness.
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Mitogen-activated protein kinase pathways
The mitogen-activated protein kinase (MAPK) pathways
play crucial roles in cell proliferation, differentiation, gene
expression, apoptosis, metabolism and motility [1-5]. A
typical MAPK pathway consists of a cascade of three con-
secutive phosphorylation events exerted by serine/threo-
nine kinases known as MAPK kinase kinase (MAPKKK or
MAP3K), a MAPK kinase (MAPKK or MAP2K), and a
MAPK (Figure 1, [1-5]).
Substrates of MAPKs include protein kinases desig-
nated as MAPK-activated protein kinases (MAPKAPK).
The human MAPKAPK family comprises the ribosomal-
S6-kinases (RSK1-4), the MAPK-interacting kinases
(MNK1 and 2), the mitogen-and stress-activated kinases
(MSK1 and 2), and MAPKAPKs MAPKAPK-2 (MK2),
MAPKAPK-3 (MK3), and MAPKAPK-5 (MK5) [6-10].
RSKs are downstream targets of the extracellular signal-
regulated kinases ERK1, ERK2 and ERK5, and regulate
cell growth, cell proliferation, cell survival, transcription
and translation, and cell motility [5,11-13]. MNK1 and
MNK2, which are activated in vivo by ERK1/2 and* Correspondence: ugo.moens@uit.no
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reproduction in any medium, provided the orp38MAPK, participate in transcriptional and translational
regulation, inflammatory responses, proliferation and
survival [8,14]. MSK-1 and MSK-2 operate downstream
of ERK1/2 and p38MAPK, and play versatile roles in tran-
scription, translation, inflammatory responses, and neur-
onal processes [7,10]. Of MK2, MK3 and MK5, MK2 and
MK3 are most closely structurally and functionally
related. They share 75% overall sequence identity and
are directly activated by p38MAPK [6,15]. MK2 partici-
pates in cytokines production, endocytosis, cytoskeleton
architecture, cell migration, cell cycle control, cell sur-
vival, and transcriptional regulation and may play a
causal role in infections and inflammatory diseases such
as rheumatoid arthritis, atherosclerosis, and asthma
[6,14-16]. The precise role of MK3 is not fully under-
stood because MK3 deficient mice are viable and display
no obvious phenotype. However, studies in a MK2-
deficient background indicated that MK3 can compen-
sate for the loss of MK2, while MK3 seems to inhibit
interferon-γ expression by impairing interferon regula-
tory factor 3 protein expression and activation and inhi-
biting nuclear translocation of the p65 subunit of NFκB
[17,18].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Schematic presentation of the different mammalian MAP kinase pathways. The conventional MAP kinase pathways, represented
by the MEK/ERK, JNK, p38MAPK, and MEK5/ERK5 pathways, consist of a module of three kinases that subsequently phosphorylate and active each
other. The MAPK kinase kinase (MAP3K) phosphorylates MAPK kinase (MAP2K), which in turn phosphorylates MAPK. Downstream of MAPK are
substrates including other protein kinases referred to as MAPK-activated protein kinases (MAPKAPK). The atypical pathways include ERK3, ERK4,
ERK7, ERK8, and NLK. MAPKs can converge to different MAPKAPK as shown in this figure.
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The human ERK3 (~100 kD) and ERK4 (~70 kD) pro-
teins have a similar structural organization and are 73%
identical in their kinase domain. Both are atypical MAPK
because their activation loop lacks a phosphoacceptor
Tyr residue (conserved TXY motif ), but contains a Ser-
Glu-Gly (SEG) motif [5,19]. ERK4 is a relative stable pro-
tein, while ERK3 is rapidly degraded via the ubiquitin-
proteasome pathway [20-23]. When overexpressed in
cells, both ERK3 and ERK4 redirect MK5 exclusively to
the cytoplasm [20,21,24]. ERK3 and ERK4 can be acti-
vated by the group I p21-activated protein kinases PAK1,
PAK 2, and PAK3 [25,26].
ERK3 deficient mice on a C57BL/6 background are
non-viable [27]. Approximately 40% of the born offspring
die within 15 min of delivery because of acute respiratory
failure, while the survivors display severe phenotypic
changes such as uncoordinated movements, lack of re-
flex on pinching, infirm vocalization, and diminished
suckling reflex. The surviving animals die within 24 h
after birth. ERK3−/− mice have foetal growth restrictions
and reduced body and organ weight, but no gross mor-
phological changes. Moreover, they are characterized by
pulmonary hypoplasia and incomplete differentiation of
type II pneumocytes, confirming a role of ERK3 indifferentiation and proliferation. ERK3−/− mice display
also defects in production and/or secretion of insulin-
like growth factor II [27].
Disruption of the mapk4 gene encoding ERK4 has no
obvious effects on viability, fertility, morphology and
physiology of the mice on a mixed C57BL/6 J × 129/Sv
genetic background [28]. Moreover, knockout of the
mapk4 gene in ERK3 deficient mice does not exacerbate
their phenotype. However, ERK4-deficient animals on a
C57BL/6 J genetic background possess increased depression-
like behaviour [28]. The cellular and physiological roles of
ERK4 remain obscure.
Mitogen-activated protein kinase-activated protein kinase-
5 (MK5)
MK5 is a 54 kD ser/thr kinase that can be activated in vitro
by ERK2, JNK and p38MAPK through phosphorylation of
Thr-182 [29,30]. MK5 is ubiquitously expressed, but is most
abundant in brain, heart and platelets [29-31]. The
organization of the gene and primary sequence of the pro-
tein are well conserved in vertebrates, but a gene encoding
MK5 seems absent in invertebrates [32]. MK5 has a func-
tional nuclear localization signal and nuclear export signal
that allows the protein to shuttle between the nucleus and
the cytoplasm. In resting cells, MK5 is predominantly found
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tains the catalytic domain, while the C-terminal region is
required for ERK3 and ERK4 binding. MK5 also contains a
p38MAPK docking motif, which overlaps with the nuclear
localization signal [32].
Although the amino acid sequence and the structural
organization of MK5 show most similarity to MK2 and
MK3 (approximately 33% homology,), several unique
properties clearly distinguish MK5 from MK2/MK3. MK5
has a unique C-terminal sequence which is lacking in
MK2 and MK3 [5,6,30,32]. In contrast to MK2 and MK3,
MK5 belongs to the atypical MAPK pathways (Figure 1,
[5]). ERK3 and ERK4 are upstream activators of MK5 that
can induce phosphorylation of MK5 at Thr-182 [20,21,34-
36]. PAK-induced activation of ERK3/4 results in increased
phosphorylation of MK5 at Thr-182 and stimulated theFigure 2 Molecular mechanisms of the pro- and anti-oncogenic prope
increase the transcript levels of ERK4, but also results in constitutive activati
transcription of the erk3 gene. (4) The RNA binding protein IGB2BP can inh
MK5. (6) Active MK5 can phosphorylate Hsp27, which will affect actin remo
factor FOXO3a, which in turn will trigger transcription of microRNA mir34b
mRNA and hence the production of c-MYC, a protein that is important for
and enhances transcription of this gene. FOXO3a also reduces expression o
phosphorylation of p53 at Ser-37 stimulates the transcriptional activity of p
cycle progression. (9) ERK3 can sequester cyclin D3. By usurping cyclin D3,enzymatic activity of MK5 [25,26]. There is controversy to
whether p38MAPK can phosphorylate MK5 on Thr-182
in vivo, but recent results show that the p38β isoform can
activate MK5 in vivo [37,38]. Another activator of MK5 is
cAMP-dependent protein kinase (PKA) which phosphory-
lates MK5 at Ser-115 [24,39].
The biological role of MK5 remains incompletely
understood. MK5 knockout mice generated on a mixed
129 ×C57/B6 genetic background are viable, fertile and
display no obvious phenotype, while mk5−/− mice on a
C57BL/6 genetic background show embryonic lethality
with incomplete penetrance around E11 [35,40]. Trans-
genic mice overexpressing a constitutive active mutant of
MK5 display sex-specific changes in anxiety behaviour
and locomotor activity, but the underlying molecular
mechanisms have not been identified [41].rties of ERK3, ERK4, and MK5. (1,2) Oncogenic Ras mutants can
on of Raf. (3) Activated Raf or oncogenic BRAFV600E also stimulates
ibit translation of ERK4 mRNA. (5) ERK3 and ERK4 proteins can activate
delling and cell migration. (7) MK5 can also phosphorylate transcription
/c. mir34b/c inhibits the cell cycle and prevents translation of c-myc
cell cycle regulation. C-MYC binds to the promoter of the mk5 gene
f VEGF and may thus hamper angiogenesis. (8) MK5-mediated
53, resulting in enhanced expression of p21Cip1. p21Cip1 inhibits cell
it may cause cell cycle arrest.
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Effect of ERK3, ERK4 and MK5 on cell proliferation
Several observations disclose an involvement of the ERK3/
4-MK5 pathway in cell cycle regulation (Figures 2 and 3).
Elevated ERK3 levels result in G1 cell cycle arrest and in-
hibition of cell proliferation [22,42,43]. So far, it is not
known whether ERK4 is implicated in cell cycle regulation
because no difference in the proliferation rate between
wild-type and ERK4−/− fibroblasts was observed [28].
Overexpression of wild-type, but not kinase dead MK5Figure 3 MK5 is implicated in VEGF-mediated angiogenesis. VEGF pro
endothelial cells. This will trigger a cascade involving the MAP kinases p38
in the cytoskeletal architecture and migration of endothelial cells towards t
shown. The pathway induced by VEGF and which involves MK5 is depictedinhibited oncogenic H-Ras induced cell proliferation of
NIH3T3 cells [44]. Ectopic expression of MK5 alone also
reduced proliferation of NIH3T3 cells [45]. Oncogenic H-
Ras-induced senescence is compromised in MK5 deficient
primary murine fibroblasts and embryonic fibroblasts.
Wild-type MK5, but not a kinase-dead mutant restored
the senescence response to oncogenic Ras, indicating that
the enzymatic activity of MK5 is required [46]. Knockout
of the mk5 gene in mouse embryonal fibroblasts leads to
cell cycle arrest and proliferation inhibition [47].duced by tumour cells will bind to the VEGF receptor VEGFR2 on
and MK5. MK5 can in turn activate FAK, and this will result in changes
he tumour. A blood vessel with endothelial cells aligning the vessel is
in detail.
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human tumour tissues
A limited number of samples of a restricted selection
of cancers have been examined for mutations in the
erk3, erk4 and the mk5 gene. Silent mutations or sin-
gle amino acid substitutions have been detected in
lung, ovary and skin cancer tissue for ERK3, in lung
and skin cancer tissue for ERK4, and in lung, melan-
oma and ovary cancer samples for MK5 (Tables 1, 2,
3; [48-54]). The effect of these mutations on the bio-
logical properties of ERK3, ERK4 and MK5 needs to
be investigated, and it is has to be determined
whether these are driver or passenger mutations.
Interestingly, the L290V substitution in ERK3 was
observed in both lung and skin cancer samples
[48,51]. The E331D and D336N substitutions in ERK4
are located in the MK5 interaction motif [55]. In an
overlay assay using ERK4 peptides with wild-type se-
quence or single amino-acid substitutions bound to
cellulose membrane, the authors showed that D336N,
but not E331D reduced in vitro binding of recombin-
ant MK5. This observation may indicate that the
in vivo interaction between ERK4 D336N and MK5 is
weakened and affects the ERK4-MK5 signalling. ERK4
mutations A52V and P246T reside in the kinase do-
main, but it is not known if they affect the catalytic
activity of ERK4.Table 1 Somatic mutations in mapk6/erk3 in cancer tissues
Primary tissue Unique mutated samples % m
bilary tract 0 0%
breast 0 0%
CNS 0 0%
haematopoietic and lymphoid tissue 0 0%
kidney 0 0%










upper aerodigestive tract 0 0%
urinary tract 0 0%Altered expression of ERK3, ERK4 or MK5 in cancer tissue
The expression of proliferating cell nuclear antigen
(PCNA), a key regulator in cell cycle control, DNA repli-
cation and repair, is strongly upregulated in many
chronic myelogenous leukaemia (CML) patients. siRNA-
mediated depletion of PCNA expression in several CML
cell lines resulted in down-regulation of PAK2 and ERK3
transcript levels [56]. This may suggest that in CML
patients with enhanced PCNA expression, the levels
of PAK2 and ERK3 are also elevated and these per-
turbed expression levels may be implicated in the de-
velopment of CML. Rai and colleagues examined the
levels of ERK3 transcripts in oral tissue and peripheral
blood cells from patients with chewing-tobacco-
induced oral squamous cell carcinoma and healthy
controls [57]. They found that 37/41 (90%) of the
patients examined displayed a 5- to 8-fold increase in
ERK3 transcripts in oral cancer tissue compared to
healthy tissue. Peripheral blood cells of 8/13 (61.5%)
oral squamous cell carcinoma patients also showed
increased ERK3 mRNA levels, compared to absence
or low levels in 71% (23/31) in peripheral blood cells
of healthy individuals. Sequencing of the erk3 gene of
oral squamous cell carcinoma tissue revealed that the
coding sequence was identical with the sequence of the
erk3 gene determined from foetal skeletal muscle. How-







359 c.190 C> T : R64C [48]
c.700 G> T: G234C [48]
c.868 C>G: L290V [48]





8 c.868 C>G: L290V [51]





Table 2 Somatic mutations in mapk4/erk4 in cancer tissues
Primary tissue Unique mutated samples % mutated Total unique samples Mutation data references
bilary tract 0 0% 2
breast 0 0% 201
CNS 0 0% 477
haematopoietic and lymphoid tissue 0 0% 27
kidney 0 0% 28
large intestine 0 0% 42
lung 4 1% 359 c.354 G>A : Q118Q [49]
c.736 C>A: P246T [48]
c.993 G> T: E331D [49]
c1006G>A: D336N [48]
ovary 0 0% 84
pancreas 0 0% 31
pleura 0 0% 1
prostate 0 0% 58
salivary gland 0 0% 9
skin 3 33% 9 c.155 C> T: A52V [53]
c.340 C> T: R114C [51]
c.812A>G: K271R [53]
stomach 0 0% 34
testis 0 0% 13
upper aerodigestive tract 1 5% 20 c.841 G>A: V281M [52]
urinary tract 0 0% 2
Kostenko et al. Journal of Molecular Signaling 2012, 7:9 Page 6 of 11
http://www.jmolecularsignaling.com/content/7/1/9alterations in the non-coding region. Although it was not
tested whether all oral cancer patients with increased
ERK3 transcript levels carried the same mutations in their
erk3 gene, the authors speculated that these mutations
may affect the stability or translation efficiency of ERK3
mRNA, resulting in overexpression of ERK3. The presence
of relatively high ERK3 transcripts in peripheral blood of
healthy individuals may indicate that these individuals are
at higher risk of developing oral cancer [57].
Oncogenic mutations in the b-raf gene, especially acti-
vating V600E mutation, is very common in several forms
of cancer [58,59]. Inducible expression of oncogenic
BRafV600E in NIH3T3 cells resulted in ~10-fold increased
transcript levels of ERK3 and augmented protein levels
compared to control cells [60]. Studies with proteasomal
inhibitors demonstrated that BRafV600E exclusively regu-
lates ERK3 expression at the transcriptional level without
affecting proteasome-mediated turnover of ERK3 pro-
tein. The mechanism by which BRafV600E enhances
ERK3 transcription is not known, but knockdown of
BRafV600E in the melanoma cell line A375 or inhibition
of MEK1/2, but not p38MAPK by respectively U0126 and
SB203580, abrogated ERK3 expression. Whether ERK3
contributes to tumorigenesis in melanoma expressing
BRafV600E remains elusive because depletion of ERK3 inA375 cells did not change tumour cell proliferation,
apoptosis or angiogenesis in mice injected with A375
cells stably transfected with ERK3 shRNA [60]. PAK3 is
an upstream activator of ERK3 [25,26]. Pak3 mRNA
levels, however, were downregulated upon induction of
BRafV600E expression [60]. These results indicate that
BRafV600E-induced transcriptional upregulation of the
erk3 gene is independent of PAK3. Wang and co-
workers found that 10/21 colorectal cancer tissues had
higher ERK3 expression levels that adjacent normal mu-
cosa [61]. Elevated ERK3 protein levels are also asso-
ciated with gastric cancer. The protein levels of ERK3
were on average 3.85-fold higher in 27/42 gastric cancer
tissues compared with paired adjacent normal mucosa
samples [62]. ERK3 levels were higher in stage II and
stage III tumours than in stage I and stage IV tumours.
Metastatic lymph nodes (n = 14) had on average 6.9-fold
higher ERK3 protein levels than adjacent mucosa speci-
mens [61]. Determination of relative ERK3 transcript
levels by quantitative real-time PCR in 48 mouse salivary
gland tissues (7 normal, 13 dysplasias, and 28 adenocar-
cinomas) showed increased levels in dysplasia and
adenocarcinomas compared to normal tissue [63].
Increased ERK3 transcripts or protein levels have also
been observed in breast cancer, melanoma and non-
Table 3 Somatic mutations in mapkapk-5 in cancer tissues
Primary tissue Unique mutated samples % mutated Total unique samples Mutation data references
bilary tract 0 0% 2
breast 0 0% 201
CNS 0 0% 477
haematopoietic and lymphoid tissue 0 0% 27
kidney 0 0% 28
large intestine 0 0% 42
lung 2 1% 171 c.406 C> T: L136L [49]
c.450 G>A: K150K [49]
c.1371A>G: E457E [49]
melanoma 1 4% 25 c.890 G>A: L297E [54]
ovary 1 1% 85 c.660 + 2 T>A: intronic mutation [50]
pancreas 0 0% 31
pleura 0 0% 1
prostate 0 0% 58
salivary gland 0 0% 9
skin 0 0% 6
stomach 0 0% 34
testis 0 0% 13
upper aerodigestive tract 0 0% 19
urinary tract 0 0% 2
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lished whether increased ERK3 levels contribute to
oncogenesis.
Less is known about ERK4 and MK5 protein levels in
cancers. Lung adenomas in oncogenic K-Ras transgenic
mice contain increased ERK4 levels compared with lungs
of non-transgenic mice, but the biological relevance is
not known [67]. To our best knowledge, no aberrant
MK5 protein levels in tumours have been reported so
far.
Molecular mechanisms of the oncogenic
potentials of the ERK3/4-MK5 signalling pathway
The fine molecular mechanisms by which ERK3 prevents
cell cycle progression are incompletely understood, but
ERK3 binds cyclin D3, as well as Cdc14A (an antagonist
of cyclin-dependent kinase 1), while Cdc14A stabilizes
complex formation between ERK3 and cyclin D3 [68].
ERK3 may sequester cyclin D3, thereby inhibiting cell
cycle progression [68].
Long et al. [66] elegantly demonstrated that ERK3 pro-
motes lung cancer cell invasion in vitro and in vivo
through upregulating the expression of matrix metallopro-
teinase MMP2 and MMP10. ERK3 enhances transcription
of the MMP2 and MMP10 genes by phosphorylating the
steroid co-activator SRC-3 at Ser-857, which is essential
for the interaction of SRC-3 with transcription factorPEA3. MMP2 and MMP10 are SRC-3/PEA3 target genes
[66].
A causal role for ERK4-MK5 in metastasis was recently
proposed [69]. Insulin-like growth factor 2 mRNA-
binding protein (IGF2BP, also known as IMP, VICKz or
ZBP1) belongs to a family of highly conserved proteins
that regulate stability, location, and translation of a sub-
set of mRNAs and as such, participate in cell polarity
and migration [70,71]. IMPs are overexpressed in various
human cancers where they are implicated in the forma-
tion of lamellipodia and invadopodia, and thus may con-
tribute to metastasis [69,72-74]. A recent study by Stöhr
and co-workers unveiled a role of the ERK4-MK5 path-
way in IGF2BP- induced tumour cell migration [69].
Microarray analysis of total RNA isolated from stressed
osteosarcoma U2OS cells upon IGF2BP1knockdown
identified 74 annotated transcripts decreased ≥8-fold
compared to control cells. One of the transcripts
encodes ERK4. The authors showed that IGF2BP1pre-
vents translation of ERK4 mRNA, which antagonizes
MK5 activation and HSP27 phosphorylation. Knockdown
of IGF2BP1 promoted HSP27 phosphorylation at Ser-78
and Ser-82, while overexpressing IGF2BP1 decreased
ERK4 and phosphoHSP27 levels. While phosphoThr-182
of MK5, which is required for MK5 activation, was not
examined, the authors showed that siRNA-mediated de-
pletion of MK5, as well as inhibition of MK2/MK3/MK5
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ation. Phosphorylation of HSP27 controls actin dynamics
[reviewed in 75], and indeed IGF2BP1 knockdown-
triggered changes in the actin cytoskeleton were abol-
ished by both depletion and inhibition of MK5 [69]. The
authors used time-lapse microscopy to demonstrate that
IGF2BP1 promoted the velocity of cell migration by inhi-
biting MK5-mediated phosphorylation of HSP27. MK5-
induced HSP27 phosphorylation leads to a significant de-
crease in cell migration velocity. Thus, overexpression of
IGF2BP1 protein in cancer cells results in inhibition of
ERK4 mRNA translation and activation of MK5, and
subsequent reduction in HSP27 phosphorylation. This
promotes the velocity of tumour cell migration. Interest-
ingly, tumour cells often display elevated HSP27 levels
[reviewed in 75]. Thus increased IGF2BP1 and HSP27
protein levels both promote cell migration/invasiveness.
MK5 may exert anti- and pro-oncogenic effects as
demonstrated by two studies from the group of Sun. In a
first study, this group described that MK5 knockout mice
were more susceptible to 7,12-dimethylbenzathracene
(DMBA)-induced skin cancer [46]. The authors postulated
that MK5 suppresses the initiation stage of skin carcino-
genesis by mediating oncogene-induced senescence. The
exact mechanism by which MK5 can act as a negative
regulator in oncogenic RAS proliferative signalling is in-
completely understood, but MK5’s ability to suppress cell
proliferation relies on intact kinase activity and nuclear
localization, because neither kinase dead mutants nor
mutants that reside in the cytoplasm can prevent onco-
genic RAS-induced cell proliferation [45,46]. The authors
provided evidence that MK5 transactivates p53 through
phosphorylation of Ser-37, resulting in increased expres-
sion of p21Cip-1 and subsequently cell cycle arrest [46].
Additionally, MK5 inhibited RAS-induced JNK activity by
85% [44]. The JNK pathway is implicated in proliferation
and can act as a negative regulator of the p53 tumour sup-
pressor [76,77]. These observations suggest a dual pathway
by which MK5 prevents oncogenic RAS-induced cell pro-
liferation. The fine molecular mechanism by which MK5
interferes with the JNK pathway is not known, nor has a
functional link in cancer been established.
In a later study, the same group showed that once the
tumour is established, tumour growth was drastically
impaired in MK5−/− mice, while sustained growth and ma-
lignant progression of tumours was observed in MK5+/+
and MK5+/− mice [78]. MK5 supports tumour growth and
progression by stimulating angiogenesis. MK5 mediates
endothelial cell migration in response to vascular endothe-
lial growth factor (VEGF) and maybe additional factors
secreted by the skin tumour epithelium (Figure 3). VEGF
binds predominantly VEGF receptor 2 (VEGFR2) and this
triggers MK5 Thr-182 phosphorylation through a cascade
involving the p38MAPK isoforms α and β, but not ERK3 andERK4 [78]. Activation of the p38MAPK pathway by VEGF
has been shown to induce phosphorylation of HSP27 and
to provoke actin reorganization and migration of endothe-
lial cells [79]. Although HSP27 is a genuine substrate of
MK5 [80] and MK5 can be activated by p38MAPK, VEGF-
induced HSP27 phosphorylation was not affected in MK5
depleted human vascular umbilical veil endothelial cells.
Focal adhesion kinase (FAK) is another major regulator of
cytoskeletal organization and cell migration [81]. Yoshizuka
and colleagues demonstrated that VEGFR2-induced MK5
activation is essential for FAK activation and cytoskeletal
reorganization during migration of endothelial cells [78].
The exact mechanism for MK5-mediated FAK phosphoryl-
ation and activation remains to be solved.
A siRNA screen against the complete human kinome
revealed an increase in c-MYC protein levels in cells treated
with MK5 siRNA [82]. The authors went on to show that
MK5 induced expression of the microRNAs miR-34b and
miR-34c by phosphorylating the transcription factor
FOXO3a which binds the pre-miR-34 promoter. MK5 pre-
dominantly phosphorylates FOXO3a at Ser-215 in vivo (and
at other sites in vitro as well) and MK5-mediated phosphor-
ylation of this site is required for the upregulation of miR-
34b/c levels. The miR-34b/c binds c-myc mRNA, resulting
in reduced c-MYC protein levels. MYC protein seems to be
engaged in a negative feedback loop by binding to the MK5
promoter and enhancing expression of MK5 [82]. Because
MYC is a central regulator of the cell cycle and aberrant
MYC expression plays a central role in oncogenesis [83],
Kress and colleagues investigated the state of MK5 expres-
sion in tumour cells with increased MYC levels. MK5 ex-
pression was higher in normal colon mucosa than in
colorectal carcinoma, whereas MYC expression was weak in
normal colon epithelium, but strong in colorectal tumour
tissues. Moreover, low levels of MK5 mRNA were asso-
ciated with increased probability of the development of dis-
tant metastasis [82]. These exciting findings point to a
tumour-suppressive function of MK5. It would be interest-
ing to validate the MK5-MYC link in mk5−/− mice or in
transgenic mice overexpressing an active MK5 mutant by
examining Myc levels and the development of colon cancer
in these animals compared to wild-type mice. FOXO3a was
recently shown to repress the VEGF promoter and reduce
expression of VEGF [84]. FOXO3a also stimulates expres-
sion of miR34b, a microRNA that causes cell cycle G1 arrest
and suppresses cell invasion of melanoma cells [85,86].
Hence, MK5 may through FOXO3a-mediated phosphoryl-
ation promote angiogenesis by enhancing the expression of
VEGF, but reduce invasiveness by upregulation of miR-34b.
Conclusions
In vitro studies and animal models demonstrate that the
ERK3/4-MK5 pathway can participate in several pro-
cesses that are dysregulated in cancer, including cell
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esis. However, a bona fide role for ERK3, ERK4 and MK5
in human cancer remains to be elucidated. ERK3, ERK4
and MK5 seem to act downstream of the Ras/Raf path-
way or to be implicated in the regulation of c-Myc ex-
pression. The ras, raf and c-myc genes are amongst the
most commonly mutated genes in cancer [58,87,88]. The
lack of potent Ras and c-Myc inhibitors and the acquire-
ment of drug resistance make ERK3, ERK4, and MK5 at-
tractive targets for therapeutic drugs in tumours with
perturbed RAS, RAF or c-MYC activity. ERK3 was upre-
gulated in doxorubicin-resistent breast cancer MCF-7
cells and can be a potential target for anti-cancer drug
development [89]. Because MK5 can operate as a tumour
suppressor and a tumour promoter, drugs that hamper
or augment MK5’s activity should be designed. Some se-
lective MK5 inhibitors have been identified, but they
have not been tested in clinical trials [90-92]. No MK5
activators to stimulate its tumour suppressor property
are available, nor have any compounds that modulate the
activity of ERK3 and ERK4 been developed.
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